COLOMBO NICOLETTA

Grisham, R., Monk, B., Van Nieuwenhuysen, E., Moore, K., Fabbro, M., O'Malley, D., et al. (2025). GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER [10.1136/ijgc-2024-005919]. Detail

Vergote, I., Copeland, L., Van Gorp, T., Laenen, A., Scambia, G., Thaker, P., et al. (2025). Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. EUROPEAN JOURNAL OF CANCER, 219(26 March 2025) [10.1016/j.ejca.2025.115306]. Detail

Oaknin, A., Monk, B., de Melo, A., Kim, H., Kim, Y., Lisyanskaya, A., et al. (2025). Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. EUROPEAN JOURNAL OF CANCER, 216(5 February 2025) [10.1016/j.ejca.2024.115146]. Detail

Bogani, G., Moore, K., Ray-Coquard, I., Lorusso, D., Matulonis, U., Ledermann, J., et al. (2025). Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 193(February 2025), 30-40 [10.1016/j.ygyno.2024.12.011]. Detail

Scambia, G., Villalobos Valencia, R., Colombo, N., Cibula, D., Leath, C., Bidzinski, M., et al. (2025). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. JOURNAL OF CLINICAL ONCOLOGY, 43(12), 1408-1416 [10.1200/JCO.24.00933]. Detail